Trial Profile
A Phase I/II Clinical Trial of PXD101 in Combination With Idarubicin in Patients With AML Not Suitable for Standard Intensive Therapy.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Belinostat (Primary) ; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors TopoTarget; Valerio Therapeutics
- 17 Sep 2012 Subgroup analysis according to cytogenetic risk reported at the Annual Congress of the European Society for Medical Oncology (ESMO) in September 2012.
- 03 Jul 2012 Pfizer added as associations as reported in the European Clinical Trials Database record.
- 03 Jul 2012 Planned number of patients changed from 35 to 70 as reported by European Clinical Trials Database record.